作者
RECOVERY Collaborative Group Data Monitoring Committee of the RECOVERY Collaborative Group Sandercock Peter 31 Darbyshire Janet 32 DeMets David 33 Fowler Robert 34 Lalloo David 35 Munavvar Mohammed 36 Warris Adilia 37 Wittes Janet 38, Health records (for the RECOVERY Collaborative Group) Pinches H. 40 Bowker P. 40 Byrne-Watts V. 40 Chapman G. 40 Coleman G. 40 Gray J. 40 Rees A. 40 Mather N. 40 Denwood T. 40 Harrison D. 29 Turner G. 41 Bruce J. 42 Arkley C. 43 Rees S. 43
发表日期
2024/1/31
期刊
Nature Communications
卷号
15
期号
1
页码范围
924
出版商
Nature Publishing Group UK
简介
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the …
学术搜索中的文章
… Collaborative Group Data Monitoring Committee of the … - Nature Communications, 2024